Microbot Medical
MBOT
23 hedge funds and large institutions have $4.2M invested in Microbot Medical in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
10% more capital invested
Capital invested by funds: $3.84M → $4.2M (+$365K)
6.4% more ownership
Funds ownership: 11.3% → 17.7% (+6.4%)
0% more funds holding
Funds holding: 23 → 23 (0)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.86M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$8.31K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.49K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3.99K |
| 5 |
BlackRock
New York
|
+$622 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPIA
Steward Partners Investment Advisory
New York
|
-$19.9K |
| 2 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$6.84K |
| 3 |
Morgan Stanley
New York
|
-$6.43K |
| 4 |
Renaissance Technologies
New York
|
-$4.56K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$544 |
MBOT Hedge Fund Activity: Q4 2022 in Review
23 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Microbot Medical (MBOT) for Q4 2022, worth a combined $4.2M — up 9.5% from $3.84M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MBOT positions and 1 closed out — a net gain of 2 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.86M. The largest seller was Steward Partners Investment Advisory, cutting an estimated $19.9K.
- 23 institutional investors held Microbot Medical (MBOT) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $4.2M of Microbot Medical stock for Q4 2022, up 9.5% quarter-over-quarter.
- 3 funds opened new Microbot Medical positions in Q4 2022 and 1 closed out, a net change of +2 holders.
- The largest Microbot Medical buyer in Q4 2022 was Armistice Capital, an estimated $2.86M added.
- The largest Microbot Medical seller in Q4 2022 was Steward Partners Investment Advisory, an estimated $19.9K sold.
Based on aggregated 13F filings for Q4 2022.